Metformin for safety and benefit in people with gout

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial compares metformin to a placebo in people diagnosed with gout to gather safety and efficacy data. Participants will receive either metformin or placebo and be monitored for gout-related outcomes and adverse events over the treatment period. Key exclusions include patients with cardiovascular disease, hypertension, hyperlipidemia, diabetes, active infections, other inflammatory or autoimmune diseases, those on biologic therapies, and anyone with impaired liver or kidney function or metformin hypersensitivity. The trial is being conducted at a single site at Tanta University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.

Exclusion Criteria:

* Systemic disorders such as cardiovascular, neurological, coronary artery disease.
* Hypertension, hyperlipidemia, diabetes mellitus, active infections.
* Other inflammatory or autoimmune diseases.
* Patients on biologics,
* Cases with hypersensitivity to metformin and those with impaired liver and kidney functions.

Where it's running

• Tanta Unuversity
  Tanta, Egypt Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dotinurad in gout patients who can’t tolerate XOI or failed uricase treatment

  This trial tests whether dotinurad can lower uric acid levels in adults with gout who can’t use certain standard medicines or have not benefited from uricase.

  Recruiting at 41 sites Phase 2 Crystalys Therapeutics · Birmingham, Alabama and 40 other locations · NCT07535034

• Orienting project on crystal deposits in gout, CPPD, and osteoarthritis

  This project will follow adults with gout or CPPD and people with osteoarthritis to see if crystal deposits in joints and blood vessels change over time and relate to treatments or heart problems.

  Recruiting I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Milan, Milano · NCT07504146

• Remote monitoring for gout in primary care

  This project will test a smartphone self-management app to help adults with gout and high urate levels manage their condition alongside GP follow-up.

  Recruiting Diakonhjemmet Hospital · Oslo · NCT07490522

• Purified Cortrophin® Gel for treating acute gout flares at two dose levels

  This study will try two single injections (40 U and 80 U) of Purified Cortrophin® Gel to see which dose better and more quickly reduces pain in adults having an acute gout flare.

  Recruiting Phase 4 Massachusetts General Hospital · Boston, Massachusetts · NCT07346079

• IV PRX-115 at different dose schedules, with or without methotrexate, versus placebo for adults with gout

  This trial will test whether IV PRX-115 given on different schedules, with or without low-dose methotrexate, can lower uric acid and be safe in adults whose gout is not controlled by standard urate-lowering drugs.

  Recruiting at 35 sites Phase 2 Protalix · Glendale, Arizona and 34 other locations · NCT07280156

• Dotinurad versus allopurinol for lowering uric acid in gout

  This trial tests whether dotinurad lowers blood uric acid more than allopurinol in adults with gout.

  Recruiting at 103 sites Phase 3 Crystalys Therapeutics · Birmingham, Alabama and 118 other locations · NCT07089875

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.